181 related articles for article (PubMed ID: 23951333)
1. RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.
Sanada S; Futami K; Terada A; Yonemoto K; Ogasawara S; Akiba J; Yasumoto M; Sumi A; Ushijima K; Kamura T; Furuichi Y; Yano H
PLoS One; 2013; 8(8):e72820. PubMed ID: 23951333
[TBL] [Abstract][Full Text] [Related]
2. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.
Matsushita Y; Yokoyama Y; Yoshida H; Osawa Y; Mizunuma M; Shigeto T; Futagami M; Imaizumi T; Mizunuma H
J Ovarian Res; 2014 Nov; 7():107. PubMed ID: 25424877
[TBL] [Abstract][Full Text] [Related]
3. RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.
Futami K; Ogasawara S; Goto H; Yano H; Furuichi Y
Int J Mol Med; 2010 Apr; 25(4):537-45. PubMed ID: 20198302
[TBL] [Abstract][Full Text] [Related]
4. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
[TBL] [Abstract][Full Text] [Related]
9. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.
Yang JC; Risch E; Zhang M; Huang C; Huang H; Lu L
Future Oncol; 2017 Sep; 13(22):1981-1990. PubMed ID: 28829218
[TBL] [Abstract][Full Text] [Related]
10. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
11. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
[TBL] [Abstract][Full Text] [Related]
13. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.
O'Mara TA; Nagle CM; Batra J; Kedda MA; Clements JA; Spurdle AB
Twin Res Hum Genet; 2011 Aug; 14(4):323-7. PubMed ID: 21787114
[TBL] [Abstract][Full Text] [Related]
16. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models.
Futami K; Kumagai E; Makino H; Sato A; Takagi M; Shimamoto A; Furuichi Y
Cancer Sci; 2008 Jun; 99(6):1227-36. PubMed ID: 18422747
[TBL] [Abstract][Full Text] [Related]
18. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
[TBL] [Abstract][Full Text] [Related]
19. Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
Fridley BL; Jenkins GD; Tsai YY; Song H; Bolton KL; Fenstermacher D; Tyrer J; Ramus SJ; Cunningham JM; Vierkant RA; Chen Z; Chen YA; Iversen E; Menon U; Gentry-Maharaj A; Schildkraut J; Sutphen R; Gayther SA; Hartmann LC; Pharoah PD; Sellers TA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):529-36. PubMed ID: 22302016
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
